Crinetics (CRNX) PT Raised to $56 at Jones Trading

Go back to Crinetics (CRNX) PT Raised to $56 at Jones Trading

Crinetics Pharmaceuticals (CRNX) Reports paltusotine met Primary and All Secondary Endpoints

March 19, 2024 6:00 AM EDT

Crinetics Pharmaceuticals, Inc. (Nasdaq:... More